Seres Therapeutics Inc MCRB

Morningstar Rating
$2.93 −0.42 (12.54%)
View Full Chart

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

MCRB is trading at a LOCK|>>txHV premium.
Price
$2.91
Fair Value
LOCK|Kwdc
Uncertainty
LOCK|@x hpxy
1-Star Price
LOCK|<@%yDf&
5-Star Price
LOCK|pjx%gGR
Economic Moat
LOCK|!v!
Capital Allocation
—

News

Trading Information

Previous Close Price
$3.35
Day Range
$2.83–3.41
52-Week Range
$2.83–29.98
Bid/Ask
$2.91 / $3.08
Shares Outstanding
10.04M
Market Cap
$29.43M
Volume/Avg
247,329 / 76,597

Key Statistics

Price/Earnings (Normalized)
—
Price/Sales
14.41
Dividend Yield (Trailing)
0.00%
Dividend Yield (Forward)
0.00%
Dividend Payment Schedule
—
Total Yield
—

Company Profile

Seres Therapeutics Inc is a clinical-stage biotechnology company focused on the development of live biotherapeutic candidates. Its pipeline includes candidates such as SER-155 and SER-603, aimed at preventing and treating bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases. The company operates as a single reportable segment, mainly developing microbiome-based therapies targeting bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
66

Valuation

Metric
MCRB
Price/Earnings (Normalized)
—
Price/Book Value
0.83
Price/Sales
14.41
Price/Cash Flow
6.11
Price/Earnings
No chart available

Financial Strength

Metric
MCRB
Quick Ratio
2.04
Current Ratio
2.11
Interest Coverage
—
Quick Ratio
MCRB

Profitability

Metric
MCRB
Return on Assets (Normalized)
−47.19%
Return on Equity (Normalized)
−167.24%
Return on Invested Capital (Normalized)
−54.30%
Return on Assets
MCRB

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Vertex Pharmaceuticals Inc
VRTX
LOCK|$cH!>PLOCK|>QS?V$128B
Regeneron Pharmaceuticals Inc
REGN
LOCK|?D$K>c%LOCK|$QDzN$76B
Moderna Inc
MRNA
LOCK|W!#kS?LOCK|$w$75B
argenx SE ADR
ARGX
LOCK|%mz?p@zLOCK|DX$60B
BeOne Medicines Ltd ADR
ONC
LOCK|!H?x&#>LOCK|%?$44B
Alnylam Pharmaceuticals Inc
ALNY
LOCK|<CV<<z>LOCK|C^%t^$31B
Royalty Pharma PLC Class A
RPRX
LOCK|!!?Vb&#nLOCK|KCL?%$26B
BioNTech SE ADR
BNTX
LOCK|&B!k&jjLOCK|^@$24B
Incyte Corp
INCY
LOCK|H@pCx<fLOCK|zJx$24B
Jazz Pharmaceuticals PLC
JAZZ
LOCK|WPM><ChLOCK|jK$15B

Sponsor Center